BioSpace News Archive

Laekna Therapeutics, an emerging innovative pharma company based in China’s “Zhangjiang Pharma Valley” and New Jersey in the U.S. and focused on developing new groundbreaking innovative therapies to treat cancer and liver diseases, announced that it will present the results from two clinical studies on the treatment of prostate cancer at the European Society for Medical Oncology Congress 2021.

RELIEF THERAPEUTICS Holding AG announced that it has entered into a definitive agreement with two U.S. institutional investors to purchase in a private placement an aggregate of 71,428,572 shares of Relief common stock at a purchase price of CHF 0.21 per share.

Sun Pharmaceutical Industries Ltd., “Sun Pharma” and includes its subsidiaries and/or associate companies) and Cassiopea SpA, a specialty pharmaceutical company developing and preparing to commercialize prescription drugs with novel mechanisms of action to address long-standing essential dermatological conditions, announced the signing of License and Supply Agreements for Winlevi® in the United States and Canada.

RadNet, Inc., a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of owned and operated outpatient imaging centers, announced that it will host a conference call to discuss its second quarter 2021 financial results on Monday, August 9th, 2021 at 7:30 a.m. Pacific Time.

Twist Bioscience Corporation today announced they generated potent, binding antibodies to an undisclosed oncology target for Twist’s internal pipeline of antibody candidates.

Strategic acquisition of leading pharmacy SaaS solutions provider supports the Autonomous Pharmacy vision and expands Omnicell’s Advanced Services portfolio

Cognito Therapeutics Presents New Clinical Data Demonstrating Disease-Modifying Effects of Gamma F requency Neuro-modulation on Cognitive Function and Brain Atrophy in Alzheimer’s Disease at AAIC 2021

Minerva Neurosciences, Inc. today announced that it will release financial results and business updates for the second quarter of 2021 on Monday, August 2, 2021. The Company will host a webcast and conference call that day at 8:30 a.m. Eastern Time to discuss these results and updates.

Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended June 30, 2021 after the market close on Monday, August 9, 2021.

Acura Pharmaceuticals, Inc. (OTCQB: ACUR) today announced an amendment to its License, Development and Commercialization Agreement (“Agreement”) regarding Acura’s LIMITx™ LTX-03 product candidate with Abuse Deterrent Pharma, LLC (“AD Pharma”) to extend the FDA Acceptance Date for LTX-03 (“NDA Acceptance Date”) to February 28, 2022.